New Therapeutic Approaches to the Treatment of Dyslipidemia 2: LDL-C and Lp(a).
Kyung An KimHun-Jun ParkPublished in: Journal of lipid and atherosclerosis (2022)
Dyslipidemia is an important risk factor for atherosclerotic cardiovascular disease (ASCVD). There are abundant and unequivocal data to indicate that low-density lipoproteins (LDL) are a cause of ASCVD. Reduction of plasma low-density lipoprotein cholesterol (LDL-C) by medical therapy such as statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have proven to significantly reduce the risk of cardiovascular events. However, for many reasons, many patients are not able to achieve LDL-C levels recommended by guidelines on currently available therapies. This has led to the development of new drugs lowering LDL-C, such as inclisiran, bempedoic acid, and evinacumab, in the hope of reducing cardiovascular (CV) risk. Drugs targeting lipoprotein (a) (Lp[a]) also have a role in the prevention of atherosclerosis, with genetic studies having established that 20%-30% of the human population inherits plasma Lp(a) levels in the atherogenic range. In this paper, we will review the recent progress made in the approaches to LDL-C and Lp(a) therapeutic modulation.
Keyphrases
- low density lipoprotein
- cardiovascular disease
- cardiovascular events
- endothelial cells
- coronary artery disease
- end stage renal disease
- healthcare
- type diabetes
- newly diagnosed
- stem cells
- metabolic syndrome
- cardiovascular risk factors
- prognostic factors
- electronic health record
- cancer therapy
- bone marrow
- drug delivery
- copy number
- cell therapy
- patient reported